申请人:Hoffman-La Roche Inc.
公开号:US05561150A1
公开(公告)日:1996-10-01
Compounds of the formula ##STR1## wherein R.sup.1 to R.sup.4 each are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or phenyl; R.sup.5 is hydrogen or lower alkyl, R.sup.6 is hydrogen, lower alkyl or lower alkoxy; X is --(CR.sup.7 R.sup.8).sub.n -- or --CH.dbd.CH--; R.sup.7 and R.sup.8 are hydrogen or lower alkyl and n is 1 or 2, as well as pharmaceutically acceptable salts of basic compounds of formula I, bind to serotonin receptors, and thus are useful in treating central nervous system disorders.
化合物的公式为##STR1##其中R.sup.1到R.sup.4分别为氢,羟基,卤素,较低的烷基,较低的烷氧基或苯基; R.sup.5为氢或较低的烷基,R.sup.6为氢,较低的烷基或较低的烷氧基; X为--(CR.sup.7 R.sup.8).sub.n --或--CH.dbd.CH--; R.sup.7和R.sup.8为氢或较低的烷基,n为1或2,以及公认的药用化合物的盐I的碱性化合物,结合到5-羟色胺受体,因此在治疗中枢神经系统疾病方面是有用的。